Ten Long-Term Impacts of COVID-19 on Biopharma
August 25, 2020 Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski…
Home / Intelligence
P&MA Assessment to Support BD&L Decision-Making
Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making. Geographic Scope: Client Situation The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making. Trinity’s Solution Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for…
Cross-Functional Launch Strategy Alignment Workshop
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan. Geographic Scope: Client Situation: The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks. Trinity’s Solution: Trinity conducted targeted secondary research to determine the existing mNSCLC…
Biosimilar Differentiation Strategy
Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries. Geographic Scope: Client Situation: The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars. Trinity’s Solution Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185…
Strategic Recommendations About Potential Actions to Shape Bone Health Policy
Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets. Geographic Scope: Client Situation The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy. Trinity’s Solution Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space. Trinity then conducted exhaustive secondary research within each analogue disease area to understand the…
COVID-19 Briefing Series: Considerations for Forecasting the Spread of COVID-19
Companies throughout the life sciences industry are looking for the best ways to model scenarios for the future of COVID-19 and incorporate those decisions into their forecasting and decision-making. Publication Access Form…
Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World
July 14, 2020 Executive Summary Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptakePayers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritizationPharmacy benefit managers (PBMs) have taken a leadership role in facilitating a pathway for digital therapeutics adoption, and they are likely…
Commercial VP/SVP Pipeline Development for Women in Life Sciences
A life science company engaged TGaS Advisors to: Investigate drivers for gender diversity in VP/SVP commercial rolesBenchmark high-performing companies (in/ex industry) with above-average numbersof women in executive rolesBenchmark the key competencies and skills of women in executive commercial roles Complete the form below to view the brief…
2019 NRDL: Insights for Future Pricing Negotiations in China
June 2, 2020 Executive Summary China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers…
COVID-19 Briefing Series: Impact of COVID-19 on New Product Planning
Trinity explores some of the immediate challenges presented to New Products Planning (also known as Early Commercial Planning or New Product Commercialization) groups. Publication Access Form…
Sign up for the latest intelligence
By signing up, you are agreeing to our Privacy Policy.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.